Clinical trial · Observational
Assessment the Cancer Risk of Indeterminate Thyroid Nodules Through Integration of Clinical, Ultrasonographic and Multiomic Features
A Novel, Multimodal, Machine-learning Grounded Approach to Assess the Oncological Risk of Indeterminate Thyroid Nodules
NCT05428371CI-TRIAL-00059264THYOMICSnot yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Indeterminate thyroid nodules have a mild risk of malignancy (15-30%). The aim of our study is to individuate new biomarkers of thyroid carcinoma through multiomic analyses of blood samples and of specimen samples of patients with indeterminate thyroid nodules.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
| Thyroid Nodule | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Multiomic analyses of blood and surgical specimens | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Thyroid carcinoma
- description
- Patients with indeterminate thyroid nodule and pathological diagnosis of thyroid carcinoma
- interventionNames
- Diagnostic Test: Multiomic analyses of blood and surgical specimens
- label
- Follicular adenoma
- description
- Patients with indeterminate thyroid nodule and pathological diagnosis of follicular adenoma
- interventionNames
- Diagnostic Test: Multiomic analyses of blood and surgical specimens
Primary outcomes (1)
- measure
- Identification of biomarkers of thyroid carcinoma
- timeFrame
- 50 months
- description
- Identification of alterations in cfDNA length and integrity, presence of SNPs in cfDNA, alterations of serum proteome predictive of thyroid carcinoma
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with indeterminate thyroid nodules (Class III and Class IV according to Bethesda Classification of thyroid nodules) Exclusion Criteria: * Patients with concomitant thyroid nodules of Bethesda Class V or Class VI * Patients with preoperative diagnosis of lymph node metastases of central or lateral neck compartment * Patients with distant metastases
References
Publications (0)
Data not yet available
No reference posted for this study.